Potent and selective 5-HT2C agonist (IC50 values are 12 and 633 nM for 5-HT2C and 5-HT2A receptors respectively). Displays high affinity for the 5-HT2B receptor (Ki = 38 nM) but acts as an inverse agonist. Active in vivo; inhibits scratching in a mouse model of OCD.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 218.29. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.58 mL||22.91 mL||45.81 mL|
|5 mM||0.92 mL||4.58 mL||9.16 mL|
|10 mM||0.46 mL||2.29 mL||4.58 mL|
|50 mM||0.09 mL||0.46 mL||0.92 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
If you know of a relevant reference for 1-Methylpsilocin, please let us know.
View Related Products by Product Action
Keywords: Potent selective 5-HT2C agonists Serotonin Receptors 5-HT2C Receptors
Citations for 1-Methylpsilocin
Citations are publications that use Tocris products.
Currently there are no citations for 1-Methylpsilocin. Do you know of a great paper that uses 1-Methylpsilocin from Tocris? If so please let us know.
Literature in this Area
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.